Clinical trials
Moderately to Severely Active Crohns Disease clinical trials
Below are recruiting moderately to severely active crohns disease clinical trials, each written for real people, not researchers. We’re tracking 87 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07845487RecruitingPhase 2
Study of PALI-2108 for moderate to severe ulcerative colitis
This trial tests an experimental drug called PALI-2108 against a placebo (a dummy treatment) for people with moderate to severe ulcerative colitis. It aims to see if PALI-2108 can help reduce symptoms and improve quality of life.
Sun City, ArizonaAges 18–75 - NCT07697456RecruitingPhase 2
Study of advanced therapies for Crohn's or ulcerative colitis
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
Dothan, AlabamaAges 18–75 - NCT07663526RecruitingPhase 4
Tabellvi for moderate to severe Crohn's disease in adults
This trial tests Tabellvi (adalimumab) for adults with moderate to severe Crohn's disease who haven't responded well to steroids or other treatments. It aims to see if this medication can help control symptoms and improve quality of life.
Fuyang, AnhuiAges 18–70 - NCT07577843RecruitingPhase 3
Testing JNJ-78934804 for moderate to severe Crohn's disease
This study tests a new drug called JNJ-78934804 for people with moderate to severe Crohn's disease who have not responded well to or can't tolerate current treatments. The goal is to see if this drug can reduce inflammation and symptoms in the digestive tract.
Anaheim, CaliforniaAges 18 years+ - NCT06059989RecruitingPhase 3
Testing a new form of infliximab for Crohn's disease
This trial is testing a new way to give infliximab, a treatment for moderate to severe Crohn's disease, as a shot under the skin. It's for people who haven't gotten better with other treatments or need strong medication right away.
Amsterdam, North HollandAges 18–80 - NCT07564505RecruitingPhase 4
Adalimumab Safety and Effectiveness in Children With Crohn's Disease
This study tracks how well and how safely a medicine called adalimumab works in children ages 6–17 with moderate-to-severe Crohn's disease (a condition causing inflammation in the digestive tract). Your child's doctor has already decided adalimumab is appropriate for them, and this study simply collects information about how they respond to it.
Guangzhou, GuangdongAges 6–17 - NCT07499232RecruitingPhase 3
Guselkumab vs Risankizumab for Crohn's disease
This trial compares two drugs, guselkumab and risankizumab, to see which works better for people with moderate-to-severe Crohn's disease. Both are given as injections and aim to reduce inflammation in the gut.
Dothan, AlabamaAges 18 years+ - NCT07415044RecruitingPhase 2
Study of LY4268989 for moderate to severe ulcerative colitis
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
Phoenix, ArizonaAges 18–80 - NCT07385131Recruiting
Steroid before infliximab for inflammatory bowel disease
This study tests whether giving a steroid (dexamethasone) before an infliximab infusion can prevent allergic reactions in people with moderate-to-severe Crohn's disease or ulcerative colitis. If you qualify, you will receive either the steroid or a placebo before your infliximab treatment.
Hangzhou, ZhejiangAges 14–80 - NCT07314606Recruiting
Diet plus infliximab for kids with Crohn’s
This study tests if a special diet (called CDED) combined with infliximab (a biologic drug) is more effective than infliximab alone for children with newly diagnosed or relapsed moderate-to-severe Crohn’s disease. It aims to improve gut healing and reduce inflammation.
Vancouver, British ColumbiaAges 9–17 - NCT07298421RecruitingPhase 3
Testing afimkibart for children with Crohn's disease
This trial tests a medicine called afimkibart for children with moderately to severely active Crohn's disease. It aims to see how well the drug works and how safe it is when used for both starting and ongoing treatment.
New York, New YorkAges 2–17 - NCT06902987RecruitingPhase 1
Upatinib for anal fistulas in Crohn's disease
This trial tests whether upatinib can help heal active anal fistulas in people with moderate to severe Crohn's disease. If you have an anal fistula that is causing pain or drainage, this study may offer a new treatment option.
Guangzhou, GuangdongAges 18–70 - NCT06890637Recruiting
Fecal transplant and diet change for Crohn's disease
This trial tests whether a fecal transplant (putting healthy bacteria into your gut) combined with dietary changes can help control active Crohn's disease. It is for people who need stronger treatments or have stopped responding to their current therapy.
Kochi, KeralaAges 18–75 - NCT06890650Recruiting
Fecal transplant and diet for new Crohn's disease
This study tests whether a combination of fecal transplant (transferring healthy bacteria from a donor) and dietary changes can help control disease activity in people newly diagnosed with Crohn's. It is for those with mild to moderate symptoms who have not yet taken any Crohn's medications.
Kochi, KeralaAges 18–75 - NCT07229950RecruitingPhase 2
Experimental tablet for moderate to severe Ulcerative Colitis
This trial tests an experimental tablet, HRS-7085, for people with moderate to severe Ulcerative Colitis who haven't gotten enough help from standard treatments. The goal is to see if the drug can reduce inflammation and improve symptoms.
Chengdu, SichuanAges 18–75 - NCT07196722RecruitingPhase 2/Phase 3
Testing icotrokinra for moderate to severe Crohn's disease
This study tests a new medicine called icotrokinra for people with moderate to severe Crohn's disease who have not responded well to other treatments. It aims to see if icotrokinra can help reduce symptoms and improve gut health.
Chandler, ArizonaAges 18 years+ - NCT07184931RecruitingPhase 3
Testing duvakitug for active Crohn's disease
This study tests a new drug called duvakitug for people with moderately to severely active Crohn's disease who haven't responded well to other treatments. It aims to see if the drug can reduce symptoms and improve quality of life.
Peoria, ArizonaAges 16–80 - NCT07184944RecruitingPhase 3
Study of Duvakitug for moderate to severe Crohn's disease
This study tests a new drug called duvakitug to see if it can help maintain improvement in people with moderate to severe Crohn's disease. It's for patients who have already responded to treatment in a previous study.
Colorado Springs, ColoradoAges 16–80 - NCT07158242RecruitingPhase 3
Study of a Medication for Children with Active Ulcerative Colitis
This study is testing an investigational medication for children with ulcerative colitis that has not responded well to standard treatments. It aims to see if the drug is safe and effective in reducing symptoms.
Aurora, ColoradoAges 2–17 - NCT04187820Recruiting
Acupuncture for mild to moderate Crohn’s flare
This trial tests whether acupuncture can help calm an active Crohn’s disease flare that is mild to moderate. It may be an option if standard Crohn’s medicines like steroids, immunosuppressors, and anti-TNF drugs are not working for you or you can’t tolerate them.
Shanghai, Shanghai MunicipalityAges 16–70 - NCT07078994RecruitingPhase 2
Study of a new drug for moderate to severe Crohn's disease
This trial tests a new medicine called BCD-261 for people with moderate to severe Crohn's disease that has not responded well to other treatments. It aims to see if the drug can reduce symptoms and inflammation.
Barnaul, Altayskiy KrayAges 18–75 - NCT07034664Recruiting
Ultrasound to predict Guselkumab response in Crohn's disease
This trial tests if a medication called Guselkumab can help people with moderate to severe Crohn's disease. It uses a special ultrasound to see how the bowel responds to treatment.
Changsha, HunanAges 18–80 - NCT05928039RecruitingPhase 4
Choosing the best first biologic for Crohn’s in the ileum
This Phase 4 trial tests which type of biologic medicine works best as the first treatment for people with moderate-to-severe Crohn’s that mainly affects the ileum. It may help you and your care team choose a more effective first option, based on which strategy leads to better control of symptoms and intestinal inflammation.
Calgary, AlbertaAges 18 years+ - NCT06937099RecruitingPhase 3
Testing two drugs for Crohn's with weight issues
This trial tests two study drugs, mirikizumab and tirzepatide, in people with moderate to severe Crohn's disease who also have overweight or obesity. The goal is to see if these treatments can help control Crohn's symptoms and inflammation.
Dothan, AlabamaAges 18–70
Hear when a new Moderately to Severely Active Crohns Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Moderately to Severely Active Crohns Disease trials by city
Studies with a site in or near these metro areas.
Moderately to Severely Active Crohns Disease trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for moderately to severely active crohns disease?
- Yes. Clin2 currently lists 87 recruiting moderately to severely active crohns disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a moderately to severely active crohns disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a moderately to severely active crohns disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.